The $200 Billion Battle Over Bioequivalence: Are Generic Drugs Truly the Same?
Imagine paying hundreds of billions of dollars annually for medications that, despite being labeled as "generic," might not be as identical as we’ve been led to be…
Prove It’s the Same: The $200 Billion Bioequivalence Fight Reshaping Generic Drugs Read Post »
In the relentless race to bring life-saving drugs to market, every second counts. Yet, despite the urgency, many pharmaceutical companies find themselves ensnared in a complex web of regulatory hurdles, costly failures, and lengthy development timeline…
In the high-stakes world of pharmaceutical pricing, recent legislative shifts are sending shockwaves through the industry—and the ripple effects are just beginning to be felt.
The IRA Price Reset: A Game-Changer or Just the Beginning?
The Inflation Red…
The IRA Price Reset: What It Actually Does to Pharma Pricing — and What Comes Next Read Post »
The Patent Wall Crumbles: How Secondary Abandonment Is Reshaping the Future of Drug Innovation
In the high-stakes world of pharmaceutical innovation, the relentless pursuit of extending patent exclusivity has long been a strategic game. For decades, &q…
When the Patent Wall Crumbles: Secondary Abandonment and the Death of Drug Evergreening Read Post »
In the high-stakes world of pharmaceuticals, innovation alone isn’t enough. The real game-changer? Strategic patent licensing—unlocking hidden value, accelerating drug development, and gaining a competitive edge in an ever-evolving landscape. Yet, many…
The Strategic Playbook for Identifying and Securing Drug Patent Licensing Opportunities Read Post »
In the relentless race to develop groundbreaking new medicines, the pharmaceutical industry often overlooks a powerful, underutilized strategy: drug repurposing. As highlighted in the recent Drug Patent Watch blog post, “No Patents, No Problem? The Unt…
No Patents, No Problem: The Untapped Power of Drug Repurposing Read Post »
In the high-stakes world of pharmaceutical innovation, the race to bring a new drug to market is only part of the story. Once a blockbuster drug hits the shelves, the real battle begins—defending market share against a flood of generic competitors eage…
Beyond the API: Mapping the Secondary Patent Thicket to Forecast Generic Entry Read Post »
In the fiercely competitive world of specialty pharmacy, margins are razor-thin, and every dollar counts. But what if there was a way to double your margins—immediately—just by understanding a critical industry shift?
The Launch of Generics: A Double-…
Double Your Specialty Pharmacy Margins the Day Generics Launch Read Post »
In the high-stakes world of pharmaceuticals, blockbuster drugs are the crown jewels—massively profitable, yet perilously vulnerable to patent challenges and generic threats. The question isn’t just about developing groundbreaking medicines; it’s about …
Defend Your Blockbuster Drug. Here’s the Playbook. Read Post »
ð¨ The Truth About Drug Patents and Stock Success: Overnight Millionaires or Decades-long Marathon? ð¨
In the high-stakes world of biotech and pharmaceuticals, the narrative often goes like this: secure a patent, and overnight, your company transfo…
Get new actionable insights and updates from BiotechBlog
